NeuroDerm to present trial data at Parkinson’s conference
Last updated: 08:58 16 Jun 2016 EDT, First published: 03:58 16 Jun 2016 EDT
NeuroDerm Ltd (NASDAQ:NDRM), is to present the design and data of its ongoing Phase II clinical trial of ND0612H for the treatment of Parkinson’s diseases.
It will be presented at the 20th International Congress on Parkinson’s Disease and Movement Disorders taking place June 19 to June 23, 2016 in Berlin, Germany.
ND0612H’s first efficacy trial started in December 2015 and is a multicenter, open-label, rater-blind Phase II study.
In all, the trial, designed to investigate the safety and tolerability, will enroll 36 Parkinson's disease patients whose symptoms are not adequately controlled with oral medications.
The clinical-stage pharma company developing drugs for central nervous system (CNS) diseases, will also announce pre-clinical data investigating ND0701, its new product candidate for the treatment of Parkinson’s disease.
